PDGFB Breakapart Probe LPH031

Some cases of CML have constitutive activation of the gene for PDGFRβ which encodes a receptor for tyrosine kinase. The activation is usually caused by a t(5;12)(q32;p13) translocation which results in the ETV6-PDGFRβ fusion gene. The drug imatinib mesylate (Gleevec) specifically inhibits the kinase activity of PDGFRβ and has shown efficiency in the treatment of chronic myeloid leukaemia and gastrointestinal stromal tumours.